Zacks Investment Research upgraded shares of Innovus Pharmaceuticals (OTCMKTS:INNV) from a sell rating to a hold rating in a research note released on Wednesday.
According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “
Separately, ValuEngine upgraded shares of Innovus Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, May 2nd.
Shares of OTCMKTS INNV opened at $0.11 on Wednesday. The stock has a market cap of $21.83 million, a P/E ratio of -2.81 and a beta of 3.82. Innovus Pharmaceuticals has a 12-month low of $0.08 and a 12-month high of $0.21.
Innovus Pharmaceuticals (OTCMKTS:INNV) last issued its quarterly earnings results on Monday, April 2nd. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $2.38 million for the quarter. Innovus Pharmaceuticals had a negative return on equity of 273.00% and a negative net margin of 51.76%. analysts forecast that Innovus Pharmaceuticals will post -0.01 earnings per share for the current year.
Innovus Pharmaceuticals Company Profile
Innovus Pharmaceuticals, Inc, a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality.
Get a free copy of the Zacks research report on Innovus Pharmaceuticals (INNV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Innovus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.